These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38022633)

  • 1. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
    Quadri I; Reneau JC; Hanel W; Chung CG
    Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
    Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
    Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
    Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
    Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
    Stuver R; Geller S
    Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
    Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
    J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
    [No Abstract]   [Full Text] [Related]  

  • 11. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
    Muszbek N; Remak E; Xin Q; McNamara L; Jones T
    J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
    Wong HK; Mishra A; Hake T; Porcu P
    Br J Haematol; 2011 Oct; 155(2):150-66. PubMed ID: 21883142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
    Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
    J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
    Trager MH; Geskin LJ
    G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.